AT-1501 (anti-CD40L)

Drug Name: AT-1501 (anti-CD40L)
Company: Anelixis Therapeutics
Location: US – Massachusetts
Drug Type: Protein Biologic
Conditions: ALS
Mechanism Type: Immunomodulation
Mechanism: The blocking antibody to CD40L is designed to modulate the immune response associated with disease progression in ALS.
U.S. Status for ALS: Phase I

[1] AT-1501: An Anti CD40L Antibody Anelixis Therapeutics, 2018. Accessed 4 Dec 2018 from the Anelixis Therapeutics website.

Last updated December 28th, 2015

Share this: